Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement

Executive Summary

Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin

You may also be interested in...



Neurontin Liability Suits Take Personal Twist With Witness Intimidation Charge

When you hear about witness intimidation in a drug case, you usually don't think an Rx kingpin is involved. But Pfizer's use of a private detective in the first Neurontin liability case to go to trial has produced a behind-the-scenes drama that could spill over into subsequent litigation

Neurontin Liability Suits Take Personal Twist With Witness Intimidation Charge

When you hear about witness intimidation in a drug case, you usually don't think an Rx kingpin is involved. But Pfizer's use of a private detective in the first Neurontin liability case to go to trial has produced a behind-the-scenes drama that could spill over into subsequent litigation

Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August

Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist

Related Content

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel